PD-L1 IHC 22C3 pharmDx (13) was developed to detect PD-L1 expression and facilitate the safe and effective use of the PD-1 inhibitor pembrolizumab in patients with non–small cell lung cancer (NSCLC) (20). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.